Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
1558.HK
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.20
-50%
0.61
vs 1.24
Q4.20
-75%
0.24
vs 0.95
Q2.21
N/A
-0.69
vs 0.61
Q4.21
N/A
-0.11
vs 0.24
Q2.22
N/A
-0.04
vs -0.69
Q4.22
+226%
0.14
vs -0.11
Q2.23
+3011%
1.27
vs -0.04
Q4.23
+755%
1.21
vs 0.14
Q2.24
-34%
0.84
vs 1.27
Q4.24
N/A
-0.24
vs 1.21
Sales Growth
YoY
Current
Estimates
Q2.20
-32%
2.1B vs 3.1B
Q4.20
-92%
264.4M vs 3.2B
Q2.21
-90%
202.2M vs 2.1B
Q4.21
+169%
711.5M vs 264.4M
Q2.22
+539%
1.3B vs 202.2M
Q4.22
+245%
2.5B vs 711.5M
Q2.23
+148%
3.2B vs 1.3B
Q4.23
+26%
3.1B vs 2.5B
Q2.24
-23%
2.5B vs 3.2B
Q4.24
-59%
1.3B vs 3.1B
Return on Equity
QoQ
Q2.21
-12%
-0.12
vs 0.05
Q4.21
-1%
-0.01
vs -0.12
Q2.22
-1%
-0.01
vs -0.01
Q4.22
+2%
0.02
vs -0.01
Q2.23
+15%
0.15
vs 0.02
Q4.23
+12%
0.12
vs 0.15
Q2.24
+8%
0.08
vs 0.12
Q4.24
-2%
-0.02
vs 0.08
Institutionnal Ownership
Relative Strength
1558.HK
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
246%2025-Revenue
839%2025-EPS
2037%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Quote Panel
Key Metrics
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases, and cardiovascular diseases in the People's Republic of China. It also manufactures and sells active pharmaceutical ingredients; researches and develops medical devices and drugs, as well as biotechnology; and provides medical consulting services. The company sells its products to hospitals and medical institutions through a network of distributors. It has a strategic cooperation framework agreement with Alibaba Health Technology (China) Limited to carry out influenza special projects; Jointown Pharmaceutical Group Co., Ltd.; Guangdong Yihao Pharmaceutical Co., Ltd.; and Shenzhen HEC Industrial Development Co., Ltd, as well as strategic cooperative partnership with China National Accord Medicines Corporation Ltd. The company was formerly known as Yichang Changjiang Pharmaceutical Company Limited and changed its name to YiChang HEC ChangJiang Pharmaceutical Co., Ltd. in May 2015. The company was incorporated in 2001 and is based in Yichang, China. YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a subsidiary of Guangdong HEC Technology Holding Co., Ltd.
HKSE
0.34Â ( 2.34%)
Relative Strenght
Volume Buzz
-67%
Earning Acce
No
Dist 52w H.
5%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How 1558.HK compares to sector?